I have only a little to shed on this at this juncture, but looks like possibly a good thing for us patients. Basically the use of this Gossypol actually can cause apopotosis (direct cell death) of the 'stem' cells of PCa, which some docs believe is the reason PCa is so difficult to eradicate even with many types of drug protocols we currently have. Cannot say if this is that big of deal yet, but I would perhaps keep an eye on this one. The study is currently recruiting participants it is said. Hope we know more about
this one, soon. In Phase II trials, if it makes Phase IV then it can go to market here in USA.
NCT00666666 (Clinical trials gov. identifier)
Cancer Institute of New Jersey (NCI)